There are many reasons being given by the EU and the U.K. that you have just acknowledged are critical in coming to terms on a waiver at the WTO, including manufacturing capabilities, quality control and the safety of the vaccines.
In that context, and given the fact that these are important players in terms of having manufacturers in their home countries, can you perhaps give us—in a very short response—some of the reasons you are so against using the existing flexibilities in CAMR, not because I think that is necessarily a better route, but given the intransigence of countries that we need in order to reach a waiver? As you pointed out, some of these were used in 2008.